aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. This is a 9.52 percent decrease over losses of $(0.42) per share from the same period last year.
Rosenblatt Maintains Neutral on Meta Platforms, Lowers Price Target to $212
Rosenblatt analyst Barton Crockett maintains Meta Platforms (NASDAQ:FB) with a Neutral and lowers the price target from $228 to $212.